Last updated: July 17, 2026
Executive summary
Astellas Pharma Inc. v. Qilu Pharmaceutical (Hainan) Co., Ltd. (N.D. Illinois, No. 3:24-cv-08217) is a patent-infringement dispute tied to Astellas’ US brand(s) and Qilu’s proposed generic entry. The case posture and infringement theories are not provided in the prompt, and no docket-specific filings (complaint, answer, infringement contentions, claim construction orders, Markman, PI/TRO, or settlement) are included. A litigation summary and patent-strength analysis cannot be produced from the available inputs.
What is the case background in Astellas Pharma v. Qilu Pharmaceutical (Hainan) 3:24-cv-08217?
No docket facts are included in the prompt (asserted patents, asserted claims, drug product, filing date, jurisdictional basis, or counsel), so a case background cannot be stated without fabricating.
What drug and patents are at issue?
The prompt does not provide the asserted active ingredient, brand name, Orange Book identifiers, or patent numbers. Without those, the patent estate and infringement scope cannot be mapped.
What is the procedural posture?
The prompt only provides the case number. It does not include procedural milestones (complaint filed date, answer date, Rule 12 motion outcomes, scheduling order, discovery start, expert disclosures, claim construction, trial date, or dispositive motion rulings).
Which patents does Astellas assert against Qilu in 3:24-cv-08217?
The prompt provides no asserted patent list. A “which patents” analysis requires patent numbers and asserted claim groupings, which are not present.
Are the asserted rights composition, formulation, method-of-use, or manufacturing patents?
No patent-type data is provided. Patent-type classification requires the asserted claims and their independent claim structures.
How many patents are asserted and which families do they belong to?
The prompt provides no asserted count or family mapping.
What is the claim-by-claim infringement theory in Astellas v. Qilu?
No infringement allegations or claim charts are provided. Claim-by-claim theory cannot be summarized without the complaint’s infringement paragraphs and any subsequent infringement contentions.
Does Astellas allege direct infringement, induced infringement, or willful infringement?
The prompt does not provide the complaint’s allegation type.
What product attributes matter (dosage form, strength, release profile, excipients)?
No accused product description is provided.
How strong is Astellas’ patent estate in this dispute?
Strength assessment requires:
- asserted patent validity and enforceability positions
- any PTAB status (inter partes review, post-grant review)
- prior art lines and prosecution history
- claim construction outcomes
- litigation rulings (summary judgment, Daubert, JMOL)
None of these are included.
What validity risks are Qilu likely asserting?
No invalidity grounds (35 U.S.C. §§ 102, 103, 112, 101) or references are included.
Is there related ANDA, 505(b)(2), or biologics pathway context?
The prompt does not state the regulatory pathway or the Orange Book listing(s) driving the suit.
When does Astellas’ exclusivity expire, and when could a generic enter?
Exclusivity and patent expiration timelines require:
- Orange Book listings (drug, NDA/ANDA numbers, listed patents, regulatory expiration, pediatric exclusivity)
- patent expiration dates by patent number
No such identifiers or dates are provided.
What are the patent expiration dates for the asserted patents?
No patent numbers are provided.
When does FDA exclusivity end for the reference listed drug?
No NDA or RLD identifiers are provided.
Is Qilu challenging Astellas’ patents via Paragraph IV, and what does that imply for timing?
Paragraph IV/§ 355(j)(2)(A)(vii) status depends on:
- the ANDA submission (or relevant 505(b)(2) regulatory submission)
- the Orange Book patent paragraph referenced
- whether the suit was filed within the statutory window
No regulatory submission data is provided.
What is the statutory 30-month stay impact?
No ANDA filing date or forfeiture/trigger events are provided.
What has claim construction or Markman ruled so far in 3:24-cv-08217?
No Markman, claim construction order, or transcript summary is provided. Without it, no analysis of claim scope, indefiniteness, means-plus-function interpretation, or infringement likelihood is possible.
Are there preliminary injunction, TRO, or other emergency motions in this case?
No docket events are provided. A TRO/PI analysis depends on:
- motion filings
- factors-of-equity arguments
- evidence submitted on likelihood of success, irreparable harm, balance of hardships, and public interest
None of these are included.
What does the settlement or ongoing resolution status show for future generic risk?
Settlement terms, if any, require:
- stipulation of dismissal
- consent judgments
- license agreements or “Covenant Not to Sue” structures
- public statements or filings
No settlement or dismissal details are included.
How does this case compare with other Astellas generic disputes against Qilu or peers?
Comparison requires a list of related Astellas litigations, outcomes, and common patent themes. None of that context is provided.
Key takeaways
- The prompt provides only the docket identifier (3:24-cv-08217) with no litigation filings or patent/regulatory details.
- A litigation summary and patent-scope analysis would require asserted patent numbers, the accused product/drug, procedural milestones, and any claim construction or dispositive rulings. Those inputs are not present.
- No defensible exclusivity or generic-entry timing can be computed without Orange Book/RLD and the asserted patent expiration dates.
FAQs
-
What is the “3:24-cv-08217” court and judge assignment for Astellas v. Qilu?
The prompt does not include the court division or judge name.
-
Which Orange Book patents are listed for Astellas’ reference drug involved in this suit?
The prompt does not include NDA number, RLD name, or Orange Book listing identifiers.
-
Is Qilu’s application an ANDA or 505(b)(2), and what is the filing date?
Not provided.
-
Have any patents been found invalid or narrowed in this case via claim construction or summary judgment?
Not provided.
-
Does this matter involve method-of-use versus formulation versus composition-of-matter claims?
Not provided.
References
No sources were provided in the prompt, and no docket documents, court filings, or Orange Book entries were included; therefore no citations can be generated without fabricating.
